Matches in SemOpenAlex for { <https://semopenalex.org/work/W776702925> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W776702925 abstract "The human enzymes NQO1 and NQO2 are cytosoloic flavoproteins that catalyze the two electron reduction of a broad range of quinone substrates. NQO1 and 2 are over-expressed in several types of tumours, consequently making them attractive targets for drug development. Inhibition of NQO1 and NQO2 has been shown to reduce the development of some cancers. However current agents demonstrate off target effects and therefore more pharmacologically applicable compounds are needed. Initially a computational screen of the NCI database identified NSC 645827, a triazoleacridin-6-one (TA) with an IC50 of 0.7 �M. From this, a range of TAs were synthesised and evaluated for their ability to inhibit NQO1 and NQO2. From these data we identified several TAs which were the most potent inhibitors of NQO2 reported. The most potent compound being 10a (98 � 10 nM), an N-oxide with low cellular toxicity and no DNA interaction. Taking the main pharmocaphore of the TA, a substructure search of the NCI database identified the imidazoacridin-6-one (IA) C1311, a known DNA binding agent and inhibitor of FLT3 kinase. Quantities of several IAs were obtained from the NCI and were investigated as potential NQO1 and NQO2 inhibitors. NSC 660841 was identified as the most potent inhibitor of NQO2 yet reported (6 � 3 nM). Compounds were further investigated for potential off target effects.Representative compounds from both series were evaluated for their ability to modulate the cytotoxic effect of doxorubicin (DOX). There was no obvious relationship between the compound structures and the toxicity of DOX. Although no clear relationship could be determined between the compounds, a novel association between DOX, NQO1 and NQO2 was established. Compound A6B1 demonstrated the ability to increase the toxicity of DOX. It is hypothesised that a combination treatment of NQO2 inhibitors and DOX could lead to a greater therapeutic response as apposed to DOX alone. In summary, the results identify TAs and IAs to have the ability to inhibit both NQO1 and NQO2. The low cellular toxicity and high inhibitor potency of the N-oxide compounds makes them a suitable tool to study the enzymes without off target effects. Also these data provide a direction for future compound synthesis" @default.
- W776702925 created "2016-06-24" @default.
- W776702925 creator A5027186305 @default.
- W776702925 date "2012-08-13" @default.
- W776702925 modified "2023-09-23" @default.
- W776702925 title "NAD(P)H Quinone Oxidoreductase 1 (NQO1) and NRH Quinone Oxidoreductase 2 (NQO2): Their inhibition by Triazoloacridinones and Imidazoacridinones" @default.
- W776702925 hasPublicationYear "2012" @default.
- W776702925 type Work @default.
- W776702925 sameAs 776702925 @default.
- W776702925 citedByCount "0" @default.
- W776702925 crossrefType "dissertation" @default.
- W776702925 hasAuthorship W776702925A5027186305 @default.
- W776702925 hasConcept C181199279 @default.
- W776702925 hasConcept C185592680 @default.
- W776702925 hasConcept C2780643102 @default.
- W776702925 hasConcept C55493867 @default.
- W776702925 hasConcept C71240020 @default.
- W776702925 hasConcept C75520062 @default.
- W776702925 hasConcept C86803240 @default.
- W776702925 hasConcept C98274493 @default.
- W776702925 hasConceptScore W776702925C181199279 @default.
- W776702925 hasConceptScore W776702925C185592680 @default.
- W776702925 hasConceptScore W776702925C2780643102 @default.
- W776702925 hasConceptScore W776702925C55493867 @default.
- W776702925 hasConceptScore W776702925C71240020 @default.
- W776702925 hasConceptScore W776702925C75520062 @default.
- W776702925 hasConceptScore W776702925C86803240 @default.
- W776702925 hasConceptScore W776702925C98274493 @default.
- W776702925 hasLocation W7767029251 @default.
- W776702925 hasOpenAccess W776702925 @default.
- W776702925 hasPrimaryLocation W7767029251 @default.
- W776702925 hasRelatedWork W1772399948 @default.
- W776702925 hasRelatedWork W1971581505 @default.
- W776702925 hasRelatedWork W1980066215 @default.
- W776702925 hasRelatedWork W2013276134 @default.
- W776702925 hasRelatedWork W2015894551 @default.
- W776702925 hasRelatedWork W2022378420 @default.
- W776702925 hasRelatedWork W2029197062 @default.
- W776702925 hasRelatedWork W2037181879 @default.
- W776702925 hasRelatedWork W2066909915 @default.
- W776702925 hasRelatedWork W2078420648 @default.
- W776702925 hasRelatedWork W2125163892 @default.
- W776702925 hasRelatedWork W2316095577 @default.
- W776702925 hasRelatedWork W2346906340 @default.
- W776702925 hasRelatedWork W2468221829 @default.
- W776702925 hasRelatedWork W811756648 @default.
- W776702925 hasRelatedWork W1983714863 @default.
- W776702925 isParatext "false" @default.
- W776702925 isRetracted "false" @default.
- W776702925 magId "776702925" @default.
- W776702925 workType "dissertation" @default.